K Number
K103302
Device Name
STEMPRO MSC SFM
Date Cleared
2011-02-18

(101 days)

Product Code
Regulation Number
876.5885
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
StemPro® MSC SFM Medium is a liquid tissue culture medium products intended for human ex vivo tissue and cell culture processing applications.
Device Description
StemPro® MSC SFM is a serum-free medium (SFM) specially formulated for the growth and expansion of human mesenchymal stem cells (MSCs). StemPro® MSC SFM enables human MSC growth and increased consistency compared to classical serum-supplemented medium. In addition, human MSCs can be expanded for multiple passages while maintaining their multipotential phenotype (i.e. ability to differentiate into osteogenic, chondrogenic, adipogenic lineages). StemPro® MSC SFM contains two components: StemPro® MSC SFM Basal Medium and StemPro® MSC SFM Supplement.
More Information

No
The document describes a tissue culture medium and its performance testing, with no mention of AI or ML technologies.

No
The device is a cell culture medium used for growing and expanding human mesenchymal stem cells ex vivo, not for direct therapeutic use in patients.

No

The device is a tissue culture medium intended for growing and expanding human cells ex vivo, not for diagnosing diseases or conditions.

No

The device is a liquid tissue culture medium, which is a physical substance, not software. The description details its chemical composition and performance in supporting cell growth.

Based on the provided information, this device is likely an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use explicitly states "human ex vivo tissue and cell culture processing applications." This aligns with the definition of in vitro diagnostics, which involve examining specimens taken from the human body.
  • Device Description: The description details a medium used for the "growth and expansion of human mesenchymal stem cells (MSCs)." This is a process performed outside the body (in vitro) on human cells.
  • Performance Studies: The performance studies mention "lack of potential toxicity of materials in the media to cells or tissue" and "demonstrate support of tissue and cell growth." These are tests performed on the medium itself to ensure its suitability for use with human cells in a lab setting.
  • Predicate Device: The predicate device listed, K100616 (Knockout™ SR Medium), is also a tissue culture medium, which are commonly classified as IVDs when intended for human ex vivo applications.
  • Special Controls Guidance Document: The mention of the "Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Tissue and Cell Culture Processing Applications" further reinforces that this type of product falls under regulatory oversight for devices used in vitro with human tissues and cells.

While the document doesn't explicitly state "In Vitro Diagnostic," the intended use, device description, and regulatory context strongly indicate that this product is intended for use in an in vitro setting with human biological material, which is the core of an IVD.

N/A

Intended Use / Indications for Use

StemPro® MSC SFM Medium is a liquid tissue culture media product intended for human ex vivo tissue and cell culture processing applications.

Product codes

NDS

Device Description

StemPro® MSC SFM Medium is a liquid tissue culture media product intended for human ex vivo tissue and cell culture processing applications. This device is a chemically defined tissue culture media used to support the growth or maintenance of human tissue or cells in culture. StemPro® MSC SFM is a serum-free medium (SFM) specially formulated for the growth and expansion of human mesenchymal stem cells (MSCs). StemPro® MSC SFM enables human MSC growth and increased consistency compared to classical serum-supplemented medium. In addition, human MSCs can be expanded for multiple passages while maintaining their multipotential phenotype (i.e. ability to differentiate into osteogenic, chondrogenic, adipogenic lineages). StemPro® MSC SFM contains two components: StemPro® MSC SFM Basal Medium and StemPro® MSC SFM Supplement.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Pre-Clinical Testing: Performance standards were established under Section 514 of the Federal Food, Drug, and Cosmetic Act in Guidance Document "Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Tissue and Cell Culture Processing Applications; Final Guidance for Industry and FDA Reviewers," issued May 16, 2001.
Specific assay tests and Life Technologies Corporation's equivalent tests:

  • Special Control Objective: Demonstrate lack of potential toxicity of materials in the media to cells or tissue and demonstrate support of tissue and cell growth. Life Technologies Corporation Knockout™ SR Medium equivalent test: StemPro® MSC SFM Performance Assay.
  • Special Control Objective: Demonstrate lack of endotoxin or pyrogen contamination. Life Technologies Corporation Knockout™ SR Medium equivalent test: Limulus Ameobocyte (LAL) test (25 USP Monograph 85).
  • Special Control Objective: Validation of Aseptic Processing and Sterility Assurance Level (SAL). Life Technologies Corporation Knockout™ SR Medium equivalent test: Determination of SAL to be >= 10-3 compliance with GMP requirements regarding aseptic processing.
  • Special Control Objective: Demonstrate Chemical purity. Life Technologies Corporation Knockout™ SR Medium equivalent test: Incoming Raw Material testing using USP, ACS, FCC, GIBCO, or Cell Culture requirements.

Stability/Shelf-Life:

  • Shelf life testing for StemPro® MSC SFM Medium using retained product stored at 2° - 8° C.
  • A minimum of one new production lot of StemPro® MSC SFM Medium is tested each year to verify that the product continues to meet the established shelf life.
  • Established shelf life: twelve months for the StemPro® MSC SFM Medium formulation.
  • Stability testing involves:
    • Demonstrating that the pH continues to meet specifications.
    • Demonstrating that the media is not cytotoxic and supports the growth of mammalian cells.
  • Results from studies indicate the container/closure system provides protection from microbial contamination.

Key Metrics

Not Found

Predicate Device(s)

K100616

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 876.5885 Tissue culture media for human ex vivo tissue and cell culture processing applications.

(a)
Identification. Tissue culture media for human ex vivo tissue and cell culture processing applications consist of cell and tissue culture media and components that are composed of chemically defined components (e.g., amino acids, vitamins, inorganic salts) that are essential for the ex vivo development, survival, and maintenance of tissues and cells of human origin. The solutions are indicated for use in human ex vivo tissue and cell culture processing applications.(b)
Classification. Class II (special controls): FDA guidance document, “Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Processing Applications; Final Guidance for Industry and FDA Reviewers.”

0

Pay 113

K103302

510(k) SummaryFEB 18 2011
Life Technologies Corporation - StemPro® MSC SFM Medium
Device Name:StemPro® MSC SFM Medium
Common/Usual Name:StemPro® MSC SFM
Classification Name:Tissue culture media for human ex vivo tissue and cell
culture processing applications (per 21 CFR § 876.5885)
Product Code:NDS
Submitter:Life Technologies Corporation
3175 Staley Road
Grand Island, New York 14072
Telephone:(716) 774-3122
Facsimile:(716) 774-0230
Email:kelli.tanzella@lifetech.com
Contact:Kelli Tanzella, Ph.D.
Date Prepared:October 11, 2010
Predicate Device:
Trade NameManufacturer510(k)
Knockout™ SR MediumLife Technologies CorporationK100616
Intended Use
StemPro® MSC SFM Medium is a liquid tissue culture media product intended for
human ex vivo tissue and cell culture processing applications.

Substantial Equivalence

The tissue culture media presented in this 510(k) submission, StemPro® MSC SFM The tissue ontal views provalent to Knockout™ SR Medium S10(k) K100616
manufactured by Life Technologies Corporation. Knockout™ SR Medium received 510(k) clearance from the FDA on May 20, 2010 as a Class II Device, and is listed under Product Code 78 NDS (Tissue culture media for human ex vivo tissue and cell culture processing applications). The 510(k) for Knockout™ SR Medium was reviewed by the gastroenterology control panel.

: :

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. ". . . .;

: Kansa : Cara :

1

K103302

  • A. These tissue culture products (StemPro® MSC SFM and Knockout™ SR Medium) are used for human ex vivo tissue and cell culture processing applications and have the same principles of operation, technological characteristics, efficacy (generic cellular growth and maintenance) and safety (consistency in chemical content and formulation, biocompatibility with cells. and purity). :
    . .

Intended Uses

StemPro® MSC SFM Medium is a tissue culture product intended for human ex vivo tissue and cell culture processing applications. This device is a chemically defined tissue culture media used to support the growth or maintenance of human tissue or cells in culture.

B. Principles of Operation and Technological Characteristics

StemPro® MSC SFM is a serum-free medium (SFM) specially formulated for the growth and expansion of human mesenchymal stem cells (MSCs). StemPro® MSC SFM enables human MSC growth and increased consistency compared to classical serum-supplemented medium. In addition, human MSCs can be expanded for multiple passages while maintaining their multipotential phenotype (i.e. ability to differentiate into osteogenic, chondrogenic, adipogenic lineages). StemPro® MSC SFM contains two components: StemPro® MSC SFM Basal Medium and StemPro® MSC SFM Supplement.

$$\text{The } \mathcal{L}{\omega} \text{-representation } \mathcal{L}{\omega} \text{ are defined by } \omega \text{ and } \omega_{\omega} \text{ are defined by } \omega_{\omega} \text{ and } \omega_{\omega}$$

C. Pre-Clinical Testing ..

Performance standards under Section 514 of the Federal Food, Drug, and Cosmetic Act have been established in Guidance Document "Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Tissue and Cell Culture Processing Applications; Final Guidance for Industry and FDA Reviewers," issued May 16, 2001. The specific assay tests and Life Technologies Corporation's equivalent tests are described below in greater detail.

| Special Control Objective | Life Technologies Corporation
Knockout™ SR Medium |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Demonstrate lack of potential
toxicity of materials in the media to
cells or tissue and demonstrate
support of tissue and cell growth | StemPro® MSC SFM Performance
Assay |
| Demonstrate lack of endotoxin or
pyrogen contamination | Limulus Ameobocyte (LAL) test (25
USP Monograph ) |
| Validation of Aseptic Processing and
Sterility Assurance Level (SAL) | Determination of SAL to be ≥ 10-3
compliance with GMP requirements |

Image /page/1/Figure/11 description: The image appears to be a high-contrast, black-and-white image with a grainy or speckled texture. The distribution of black and white pixels is uneven, with clusters of black dots scattered across the white background. There are no discernible objects or patterns, and the image lacks any clear structure or recognizable content. The overall impression is that of random noise or a heavily degraded image.

2

regarding aseptic processing
Demonstrate Chemical purityIncoming Raw Material testing using
USP, ACS, FCC, GIBCO, or Cell
Culture requirements

Stability/Shelf-Life - -

Life Technologies Corporation performs shelf life testing for StemPro® MSC SFM Medium using retained product stored at 2° - 8° C. In addition, a minimum of one new production lot of StemPro® MSC SFM Medium is tested each year to verify that the product continues to meet the established shelf life. Based on analysis of product performance over time, Life Technologies Corporation has established a shelf life of twelve months for the StemPro® MSC SFM Medium formulation. Stability testing involves the assessment of these functional aspects of media, including demonstrating: (1) that the pH continues to meet specifications; and (2) the media is not cytotoxic and supports the growth of mammalian cells. The pH is tested to demonstrate that the media is not chemically altered during its storage. In assessing cytoxicity, Life Technologies Corporation demonstrates that the media functions in supporting the growth of mammalian cells and that the media does not become toxic to mammalian cells during storage.

In addition, results from the studies indicate the container/closure system provides protection from microbial.contamination.

D. Conclusion

... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

StemPro® MSC SFM and Knockout™ SR Medium are used for human ex vivo
ticayo and coll culture processing and have the seme principles of tissue and cell culture processing applications and have the same principles of operation, technological characteristics, efficacy (generic cellular growth and maintenance) and safety (consistency in chemical content and formulation, biocompatibility with cells, and purity). Their efficacy in supporting the survival, growth, development, and maintenance of human cells or tissue culture systems has been well established in scientific publications included in this submission. StemPro® MSC SFM and Knockout™ SR Medium are manufacturer in accordance with QSR requirements and are labeled as aseptically processed. Thus, StemPro® MSC SFM is substantially equivalent to the legally marketed device intended for the human ex vivo tissue and cell culture processing applications.

K10 3302

3

Image /page/3/Picture/0 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three lines representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" encircles the eagle. The text is arranged in a circular fashion around the eagle, with the department's name at the bottom and "USA" at the top.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Kelli L. Tanzella, Ph.D. Sr. Manager, Americas Regulatory Affairs Life Technologies" Inc. 3175 Staley Road GRAND ISLAND NY 14072

FEB 18 201

Re: K103302

Trade/Device Name: StemPro® MSC SFM Medium – StemPro® MSC SFM Basal Medium and StemPro® MSC SFM Supplement for ex-vivo Tissue and Cell Culture

Regulation Number: 21 CFR §876.5885

Regulation Name: Tissue culture media for human ex vivo tissue and cell culture processing applications.

Regulatory Class: II Product Code: NDS Dated: February 17, 2011 Received: February 18, 2011

Dear Dr. Tanzella:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements; including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related

4

adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Hubert Humphrey

Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

KIO3302 510(k) Number (if known): __

Device Name: StemPro® MSC SFM Medium

Indications for Use:

StemPro® MSC SFM Medium is a liquid tissue culture medium products intended for human ex vivo tissue and cell culture processing applications.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHRE PAGE IF NEEDED)

Concurrence of CDRH, Office of Evaluation (ODE) .

Prescription Use
(Per 21 CFR 801.109)

OR

Roger M. Whang

stro-Renal, and

Over-The -Counter Use (Optional Format 1-2-96)